Key points from article :
DanDrit Biotech USA, Inc. signed an agreement to acquire Enochian Biopharma Inc.
Enochian is developing an innovative proprietary technology in the field of HIV/AIDS.
The stockholders of Enochian shall be entitled to receive as consideration 50% of the number of shares of DanDrit's common stock issued and outstanding upon the acquisition.
DanDrit plans to change its name to Enochian ImmunoScience, Inc. and relocate to Los Angeles, California.
DanDrit is a development stage, biopharmaceutical company with 15 year history developing immunotherapies for cancer.
It believes the acquisition will enhance its research and development efforts and add to its pipeline.
